Innovation and R&D

R&D and Innovation

Home page

R&D and Innovation

Product Pipeline

News Center

Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA

Viwit's Nitroglycerin Sublingual Tablets Approved by FDA

Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"

Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.

Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US!

Achievements

Viwit also attaches great importance to the protection of innovation and has applied for more than 40 invention patents for the company's R&D projects.

VIWIT

Technical Support:China Enterprise Cross-border | SEO Tags

【Business License】

Search